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5‐FU

:   5‐fluorouracil

CapOx

:   capecitabine/oxaliplatin

CI

:   confidence interval

CTCAE

:   Common Terminology Criteria for Adverse Events

ECC

:   epirubicin/cisplatin/capecitabine

EOX

:   epirubicin/oxaliplatin/capecitabine

FLOT

:   docetaxel/oxaliplatin/5‐fluorouracil/leucovorin

FOLFOX

:   5‐fluorouracil/oxaliplatin

HER2

:   human epidermal growth factor receptor 2

HR

:   hazard ratio

IQR

:   interquartile range

NCR

:   Netherlands Cancer Registry

NOS

:   not otherwise specified

OS

:   overall survival

TTF

:   time to failure

Introduction {#ijc32580-sec-0001}
============

Palliative treatment represents an important part of esophagogastric cancer care, since approximately one‐third of esophagogastric cancer patients have metastases at initial diagnoses, and curative treatment options are not available.[1](#ijc32580-bib-0001){ref-type="ref"}, [2](#ijc32580-bib-0002){ref-type="ref"} Systemic therapy can improve both survival and quality of life in these patients.[3](#ijc32580-bib-0003){ref-type="ref"}, [4](#ijc32580-bib-0004){ref-type="ref"}, [5](#ijc32580-bib-0005){ref-type="ref"}, [6](#ijc32580-bib-0006){ref-type="ref"}

However, the optimal first‐line palliative systemic therapy regimen for metastatic esophagogastric cancer patients has not yet been identified. Currently, first‐line systemic treatment usually comprises a fluoropyrimidine and a platinum compound with the addition of trastuzumab in the case of human epidermal growth factor receptor 2 (HER2) overexpression, providing a survival benefit up to 9 months compared to no systemic treatment.[7](#ijc32580-bib-0007){ref-type="ref"}, [8](#ijc32580-bib-0008){ref-type="ref"}, [9](#ijc32580-bib-0009){ref-type="ref"}, [10](#ijc32580-bib-0010){ref-type="ref"}, [11](#ijc32580-bib-0011){ref-type="ref"} Triplet therapy, in which either an anthracycline or taxane is added to the platinum‐fluoropyrimidine doublet, is suggested in international guidelines for patients in good condition,[8](#ijc32580-bib-0008){ref-type="ref"}, [10](#ijc32580-bib-0010){ref-type="ref"}, [12](#ijc32580-bib-0012){ref-type="ref"}, [13](#ijc32580-bib-0013){ref-type="ref"} but becomes increasingly controversial because of its toxicity.[6](#ijc32580-bib-0006){ref-type="ref"}, [14](#ijc32580-bib-0014){ref-type="ref"}, [15](#ijc32580-bib-0015){ref-type="ref"} Because of the lack of consensus on optimal palliative systemic treatment, making choices about the best approach for these patients is challenging, which can result in interhospital and interphysician variation in individual systemic treatment. This could eventually affect survival and quality of life, and might be the explanation for stagnating survival rates, despite an increase in the administration of palliative systemic therapy from \<10% to 40% of metastatic esophagogastric cancer patients between 1990 and 2011 in the Netherlands.[1](#ijc32580-bib-0001){ref-type="ref"}, [2](#ijc32580-bib-0002){ref-type="ref"}, [16](#ijc32580-bib-0016){ref-type="ref"}, [17](#ijc32580-bib-0017){ref-type="ref"}, [18](#ijc32580-bib-0018){ref-type="ref"}

Current practice is based on the results of several randomized controlled trials.[4](#ijc32580-bib-0004){ref-type="ref"}, [5](#ijc32580-bib-0005){ref-type="ref"}, [6](#ijc32580-bib-0006){ref-type="ref"} Because of, for example, the underrepresentation of elderly and fragile patients in these trials, the actual patient population may not be adequately reflected. Therefore, more clarity about the administration and effects of palliative systemic therapy in daily clinical practice and evidence for the optimal therapeutic approach are needed. In this nationwide study, we aimed to explore first‐line palliative systemic treatment in patients with metastatic esophagogastric cancer and the effect of treatment strategy on survival and toxicity in a real‐world setting.

Materials and Methods {#ijc32580-sec-0002}
=====================

Data collection {#ijc32580-sec-0003}
---------------

Patients with an adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction or stomach (classified as C15 and C16 according to the third edition of the International Classification of Diseases for Oncology[19](#ijc32580-bib-0019){ref-type="ref"}) diagnosed with synchronous metastases (T~1--4b~N~all~M~1~) and treated with systemic therapy were identified from the Netherlands Cancer Registry (NCR). The NCR is a population‐based registry that covers the total Dutch population of more than 17 million people and is directly linked to the pathological archive that comprises all histologically confirmed cancer diagnoses. Data on vital status were obtained by annual linkage to the Dutch Personal Records Database.

All esophagogastric cancer patients with synchronous metastases (metastases diagnosed before or within the first 5 days of the first systemic treatment cycle) treated with systemic therapy were included when diagnosed in a subset of Dutch hospitals between 2010 and 2014, and all hospitals in 2015--2016 (Fig. [1](#ijc32580-fig-0001){ref-type="fig"}). Due to capacity and financial constraints, we were able to collect additional data of approximately 50% of the patients diagnosed in 2010--2014. For this period, we selected 43 of all 80 hospitals as a representative sample of all hospitals in terms of annual number of patients, type of hospital and location in the Netherlands, and included all patients diagnosed in these hospitals between 2010 and 2014. This sample can therefore be considered as adequately reflecting the nationwide patient population and hospitals (Supporting Information Table [S1](#ijc32580-supitem-0001){ref-type="supplementary-material"}). Patient characteristics and data on treatment and follow‐up were extracted from the hospital\'s electronical health record system or medical records by specially trained data managers.

![Flowchart of patient selection.](IJC-146-1889-g001){#ijc32580-fig-0001}

Exclusion {#ijc32580-sec-0004}
---------

Patients with esophageal, gastroesophageal junction or cardia carcinoma and nonregional lymph node metastases in the head and neck region only (*n* = 153) were excluded because they could have been eligible for definitive chemoradiotherapy with potential curative intent in cases in which dissemination of metastases was limited to the supraclavicular lymph nodes (Fig. [1](#ijc32580-fig-0001){ref-type="fig"}).[19](#ijc32580-bib-0019){ref-type="ref"}, [20](#ijc32580-bib-0020){ref-type="ref"} Because the exact location of these head and neck lymph node metastases was unknown, we excluded all of these patients. Moreover, patients who received chemoradiotherapy, defined as chemotherapy with concurrent radiotherapy consisting of ≥23 fractions or a total radiation dose of ≥40 Gy, were excluded (*n* = 111). Patients who received first‐line systemic treatment outside the Netherlands were excluded (*n* = 29) as were patients without follow‐up data on vital status (*n* = 9), without information on type of administered systemic therapy regimen (*n* = 10) or who were included in a trial in which they possibly received a placebo (*n* = 9). Finally, six patients in whom the primary tumor was first considered to have a different origin than the esophagus or stomach were excluded.

Systemic therapy {#ijc32580-sec-0005}
----------------

First‐line systemic treatment was defined as the first systemic therapy (monotherapy or combination regimen) given until suspension, regardless of reason for discontinuation. A combination regimen was specified as all systemic agents starting within 3 days after the first chemotherapeutic agent started. However, if trastuzumab was added more than 3 days after the start but before the end date of the combination regimen, this was also considered first line (e.g., because of delay in determination of HER2 status). All assumptions regarding first‐line treatment can be found in Supporting Information Table [S2](#ijc32580-supitem-0002){ref-type="supplementary-material"}.

If the same regimen was restarted after a therapy break, regardless of the duration of this break, this was still considered first line. Continuation of first line was also assumed if one of the agents of the initially started regimen was discontinued and the other agent(s) continued (e.g., capecitabine monotherapy after capecitabine/oxaliplatin \[CapOx\]), as well as in the case of a switch of a single drug within the same drug group (e.g., 5‐fluorouracil \[5‐FU\]/oxaliplatin \[FOLFOX\] to CapOx). If systemic therapy was switched to a regimen containing an agent of a new drug group that was not administered in the first line (e.g., carboplatin/paclitaxel to CapOx) after progression or because of toxicity, or if an agent of a new drug group was added (e.g., oxaliplatin added to 5‐FU), this was considered second‐line treatment.

The systemic therapy strategy was classified into regimens with one, two or three therapeutic agents (monotherapy, doublet therapy and triplet therapy, respectively; all without targeted therapy), trastuzumab‐containing regimens and (nontrastuzumab) targeted therapy‐containing regimens. Subsequently, systemic therapy regimens were subdivided based on the number and type of agents, as described previously[6](#ijc32580-bib-0006){ref-type="ref"}: monotherapy; fluoropyrimidine (F) doublets (with a platinum \[but not cisplatin\], taxane \[T\] or irinotecan \[I\]); cisplatin (C) doublets (with a fluoropyrimidine, taxane or etoposide); gemcitabine (G) doublets (with a platinum/cisplatin); platinum (P; but not cisplatin)/taxane doublets; anthracycline (A) triplets (with a fluoropyrimidine and platinum/cisplatin); taxane triplets (with a fluoropyrimidine and platinum/cisplatin); trastuzumab‐containing regimens; and (nontrastuzumab) targeted therapy‐containing regimens (Supporting Information Fig. [S2](#ijc32580-supitem-0005){ref-type="supplementary-material"}).

Toxicity {#ijc32580-sec-0006}
--------

grade 3--5 systemic treatment toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE, version 4.03[21](#ijc32580-bib-0021){ref-type="ref"}) was registered in patients diagnosed between 2010 and 2014. If toxicity was registered but the grade was missing and the patient was not deceased, we considered toxicity as grade 3--4, because grades 1 and 2 were not registered in the NCR.

Overall survival and time to failure of first‐line treatment {#ijc32580-sec-0007}
------------------------------------------------------------

Overall survival (OS) was assessed from start of treatment until death or end of follow‐up. Information on vital status was updated until February 1, 2019. Time to failure (TTF) of first‐line treatment was available only in patients with complete follow‐up (i.e., patients diagnosed between 2010 and 2015). TTF was used as a proxy for progression‐free survival and calculated from the start of treatment to the first progression that resulted in termination of the regimen or end of follow‐up. All assumptions regarding TTF are included in Supporting Information Table [S1](#ijc32580-supitem-0001){ref-type="supplementary-material"}.

Statistical analysis {#ijc32580-sec-0008}
--------------------

Patient and tumor characteristics are displayed with counts and percentages, or medians and interquartile ranges (IQRs). Differences between groups were analyzed using chi‐square tests and Fisher\'s exact tests where appropriate. Kaplan--Meier curves for OS and TTF were compared using the log‐rank test. Multivariable Cox regression analyses were used to identify independently associated treatment strategies with OS and TTF, with adjustment of age, sex, performance status, number of comorbidities, year of diagnosis, tumor location, histology and metastases locations. Values of *p* \< 0.05 were considered statistically significant. Analyses were performed using SAS software (version 9.4, SAS Institute, Cary, NC).

Results {#ijc32580-sec-0010}
=======

Patient characteristics {#ijc32580-sec-0011}
-----------------------

We included 2,204 patients (Fig. [1](#ijc32580-fig-0001){ref-type="fig"}), of whom most were male (76%), with a median age of 64 (IQR, 57, 70) years (Table [1](#ijc32580-tbl-0001){ref-type="table"}). Most patients had a World Health Organisation performance status of 0--1 (55%). Adenocarcinoma was present in 93% of the patients, squamous cell carcinoma in 6% and carcinoma not otherwise specified (NOS) in 1%. Nearly half of the primary tumors were located in the esophagus (46%), followed by noncardia stomach (35%) and gastroesophageal junction or cardia (19%). Most patients had one metastasis location at diagnosis (53%).

###### 

Baseline characteristics of all patients subdivided per systemic treatment strategy

  Characteristics                                                        All patients (*n* = 2,204)   Monotherapy (*n* = 228)   Doublet (*n* = 980)   Triplet (*n* = 758)   Trastuzumab‐containing regimen (*n* = 215)
  --------------------------------------------------------------------- ---------------------------- ------------------------- --------------------- --------------------- --------------------------------------------
  Male, *n* (%)                                                                1,670 (75.8%)                158 (69.3%)             757 (77.2%)           564 (74.4%)                      171 (79.5%)
  Age, years, median (IQR)                                                      64 (57, 70)                 71 (65, 76)             64 (57, 70)           62 (53, 68)                      63 (55, 69)
  \<60                                                                          741 (33.6%)                 32 (14.0%)              306 (31.2%)           311 (41.0%)                       81 (37.7%)
  60--69                                                                        856 (38.8%)                 68 (29.8%)              404 (41.2%)           292 (38.5%)                       84 (39.1%)
  70--79                                                                        566 (25.7%)                 110 (48.2%)             251 (25.6%)           152 (20.1%)                       49 (22.8%)
  ≥80                                                                            41 (1.9%)                   18 (7.9%)               19 (1.9%)             3 (0.4%)                          1 (0.5%)
  BMI, kg/m^2^, median (IQR)                                                 24.7 (22.5, 27.7)           24.2 (21.4, 27.1)       25.0 (22.5, 27.8)     24.8 (22.6, 27.7)                24.4 (22.3, 27.7)
  \<18.5 (underweight)                                                           57 (2.6%)                   8 (3.5%)                26 (2.7%)             20 (2.6%)                         3 (1.4%)
  18.5--25 (normal weight)                                                      829 (37.6%)                 107 (46.9%)             325 (33.2%)           311 (41.0%)                       78 (36.3%)
  \>25 (overweight)                                                             779 (35.3%)                 73 (32.0%)              337 (34.4%)           299 (39.4%)                       59 (27.4%)
  Unknown                                                                       539 (24.5%)                 40 (17.5%)              292 (29.8%)           128 (16.9%)                       75 (34.9%)
  Performance status, *n* (%)                                                                                                                                              
  0 or 1                                                                       1,220 (55.4%)                104 (45.6%)             549 (56.0%)           406 (53.6%)                      143 (66.5%)
  ≥2                                                                             152 (6.9%)                 33 (14.5%)               75 (7.7%)             33 (4.4%)                        10 (4.7%)
  Unknown                                                                       832 (37.7%)                 91 (39.9%)              356 (36.3%)           319 (42.1%)                       62 (28.8%)
  Comorbidities, *n* (%)                                                                                                                                                   
  0                                                                             804 (36.5%)                 61 (26.8%)              346 (35.3%)           311 (41.0%)                       77 (35.8%)
  1                                                                             621 (28.2%)                 69 (30.3%)              271 (27.7%)           214 (28.2%)                       63 (29.3%)
  ≥2                                                                            702 (31.9%)                 94 (41.2%)              326 (33.3%)           207 (27.3%)                       65 (30.2%)
  Unknown                                                                        77 (3.5%)                   4 (1.8%)                37 (3.8%)             26 (3.4%)                        10 (4.7%)
  Tumor location, *n* (%)                                                                                                                                                  
  Esophagus                                                                    1,014 (46.0%)                66 (28.9%)              579 (59.1%)           241 (31.8%)                      116 (54.0%)
  Gastroesophageal junction or cardia                                           410 (18.6%)                 47 (20.6%)              148 (15.1%)           169 (22.3%)                       41 (19.1%)
  Stomach                                                                       780 (35.4%)                 115 (50.4%)             253 (25.8%)           348 (45.9%)                       58 (27.0%)
  Histology, *n* (%)                                                                                                                                                       
  Adenocarcinoma                                                               2,056 (93.3%)                221 (96.9%)             858 (87.6%)           739 (97.5%)                      215 (100.0%)
  Squamous cell carcinoma                                                        128 (5.8%)                  6 (2.6%)               107 (10.9%)            15 (2.0%)                            0
  Carcinoma NOS                                                                  20 (0.9%)                   1 (0.4%)                15 (1.5%)             4 (0.5%)                             0
  cT stage, *n* (%)                                                                                                                                                        
  cT1--cT3                                                                     1,200 (54.4%)                111 (48.7%)             543 (55.4%)           388 (51.2%)                      138 (64.2%)
  cT4                                                                            206 (9.3%)                 26 (11.4%)               79 (8.1%)            88 (11.6%)                        12 (5.6%)
  cTx                                                                           798 (36.3%)                 91 (39.9%)              358 (36.5%)           282 (37.2%)                       65 (30.2%)
  cN stage, *n* (%)                                                                                                                                                        
  cN0                                                                           342 (15.5%)                 45 (19.7%)              145 (14.8%)           128 (16.9%)                       21 (9.8%)
  cN1--cN2                                                                     1,474 (66.9%)                141 (61.8%)             659 (67.2%)           500 (66.0%)                      160 (74.4%)
  cN3                                                                            192 (8.7%)                  14 (6.1%)              102 (10.4%)            53 (7.0%)                        20 (9.3%)
  cNx                                                                            196 (8.9%)                 28 (12.3%)               74 (7.6%)            77 (10.2%)                        14 (6.5%)
  Histologic grade, *n* (%)                                                                                                                                                
  Well differentiated                                                            34 (1.5%)                   2 (0.9%)                19 (1.9%)             7 (0.9%)                          6 (2.8%)
  Moderately differentiated                                                     400 (18.1%)                 29 (12.7%)              179 (18.3%)           127 (16.8%)                       61 (28.4%)
  Poorly differentiated                                                         928 (42.1%)                 86 (37.7%)              410 (41.8%)           352 (46.4%)                       68 (31.6%)
  Unknown                                                                       842 (38.2%)                 111 (48.7%)             372 (38.0%)           272 (35.9%)                       80 (37.2%)
  Metastatic sites, *n* (%)                                                                                                                                                
  1                                                                            1,172 (53.2%)                131 (57.5%)             517 (52.8%)           423 (55.8%)                       94 (43.7%)
  ≥2                                                                           1,032 (46.8%)                97 (42.5%)              463 (47.2%)           335 (44.2%)                      121 (56.3%)
  Location metastases, *n* (%)[1](#ijc32580-note-0004){ref-type="fn"}                                                                                                      
  Liver                                                                        1,169 (53.0%)                120 (52.6%)             519 (53.0%)           375 (49.5%)                      142 (66.0%)
  Distant lymph nodes                                                           890 (40.4%)                 93 (40.8%)              403 (41.1%)           287 (37.9%)                       94 (43.7%)
  Peritoneum                                                                    524 (23.8%)                 62 (27.2%)              191 (19.5%)           235 (31.0%)                       30 (14.0%)
  Lung                                                                          430 (19.5%)                 41 (18.0%)              195 (19.9%)           123 (16.2%)                       66 (30.7%)
  Other                                                                         499 (22.6%)                 39 (17.1%)              236 (24.1%)           163 (21.5%)                       51 (23.7%)

Baseline characteristics of all patients, divided per systemic therapy regimen. Characteristics of patients who received targeted (nontrastuzumab) therapy (*n* = 23) were not displayed as a subgroup.

More than one location per patient possible; percentages do not add up to 100.

Abbreviations: IQR, interquartile range; BMI, body mass index; NOS, not otherwise specified; cT stage, clinical tumor stage; cN status, clinical lymph node stage.

First‐line systemic treatment regimens and strategies {#ijc32580-sec-0012}
-----------------------------------------------------

A total of 45 different first‐line systemic therapy regimens were administered (Supporting Information Fig. [S1](#ijc32580-supitem-0004){ref-type="supplementary-material"}). The most commonly administered regimen was CapOx (21%), followed by epirubicin, oxaliplatin and capecitabine (EOX; 20%), carboplatin and paclitaxel (13%), epirubicin, cisplatin and capecitabine (ECC; 10%) and capecitabine monotherapy (9%; Supporting Information Table [S3](#ijc32580-supitem-0003){ref-type="supplementary-material"}). Most patients received doublet chemotherapy (45%), followed by triplet chemotherapy (34%), monotherapy (10%), trastuzumab‐containing regimens (10%) and nontrastuzumab targeted therapy‐containing regimens (1%). The latter group was not displayed as a subgroup in Table [1](#ijc32580-tbl-0001){ref-type="table"}, and not included in the Kaplan--Meier curves because of the limited number of patients.

All but one patient treated with a trastuzumab‐containing regimen had a HER2‐positive tumor. One patient received trastuzumab monotherapy; all other patients received trastuzumab with chemotherapy. Doublet chemotherapy backbones were used in the majority of the patients (*n* = 167), of which CapOx (*n* = 73) and capecitabine/cisplatin (*n* = 65) were administered most often.

Survival {#ijc32580-sec-0013}
--------

The median OS was 7.5 (IQR, 3.7, 12.9) months. In 1,700 patients, diagnosed between 2010 and 2015 with complete follow‐up, the median TTF of first‐line systemic treatment was 4.6 (IQR, 2.0, 7.9) months.

Monotherapy resulted in lower survival rates compared to all other treatment strategies in univariable and multivariable analyses (Figs. [2](#ijc32580-fig-0002){ref-type="fig"} and [3](#ijc32580-fig-0003){ref-type="fig"}; Table [2a](#ijc32580-tbl-0002){ref-type="table"}). The OS and TTF of patients treated with doublet therapy did not differ from patients treated with triplets after adjustment for confounding (OS: adjusted hazard ratio \[HR\] 0.92, 95% confidence interval \[CI\] 0.83--1.02; TTF: HR 0.92, 95% CI 0.82--1.04).

![Overall survival of synchronous metastatic esophagogastric cancer patients. Kaplan--Meier curves displaying overall survival in patients treated with one, two or three chemotherapeutic agents (monotherapy, doublet and triplet, respectively) and in patients treated with a trastuzumab‐containing regimen, diagnosed between 2010 and 2016 (*n* = 1,981). Survival curve of patients treated with a regimen containing (nontrastuzumab) targeted therapy (*n* = 23) is not displayed.](IJC-146-1889-g002){#ijc32580-fig-0002}

![Time to failure of first‐line therapy in synchronous metastatic esophagogastric cancer patients. Kaplan--Meier curves displaying time to failure of first‐line treatment in patients treated with one, two or three chemotherapeutic agents (monotherapy, doublet and triplet, respectively) and in patients treated with a trastuzumab‐containing regimen, diagnosed between 2010 and 2015 (*n* = 1,680). Survival curve of patients treated with a regimen containing (nontrastuzumab) targeted therapy (*n* = 20) is not displayed.](IJC-146-1889-g003){#ijc32580-fig-0003}

###### 

Cox regression analyses for overall survival and time to failure of first‐line treatment per systemic treatment strategy

                                                         Overall survival (*n* = 2,204)    Time to failure of first‐line treatment (*n* = 1,700)                                                                                                                              
  ------------------------------------------------------ -------------------------------- ------------------------------------------------------- ------ ------------ --------- ------ ------------ --------- ------- ----- ------ ------------ --------- ------ ------------ ---------
  Systemic treatment strategy                                                                                                                                                                                                                                                 
  Monotherapy                                            228                                                        4.1                           1.71    1.48--1.98   \<0.001  1.67    1.43--1.96   \<0.001    205    2.5  1.51    1.29--1.77   \<0.001  1.65    1.39--1.96   \<0.001
  Doublet                                                980                                                        7.4                           Ref                           Ref                             683    4.5  Ref                           Ref                 
  Triplet                                                758                                                        7.7                           0.94    0.85--1.03    0.188   0.92    0.83--1.02    0.110     666    4.8  0.89    0.79--0.99    0.027   0.92    0.82--1.04    0.179
  Trastuzumab‐containing regimen                         215                                                       11.2                           0.62    0.53--0.72   \<0.001  0.63    0.54--0.74   \<0.001    126    6.7  0.62    0.51--0.76   \<0.001  0.62    0.51--0.76   \<0.001
  Targeted therapy‐containing regimen (nontrastuzumab)   23                                                        11.9                           0.73    0.48--1.11    0.142   0.67    0.44--1.03    0.068     20     9.2  0.54    0.35--0.86    0.009   0.53    0.33--0.83    0.006
  Age, years                                                                                                                                                                                                                                                                  
  \<60                                                   741                                                        7.8                           Ref                           Ref                             581    4.8  Ref                           Ref                 
  60--69                                                 856                                                        7.5                           1.03    0.93--1.14    0.542   1.01    0.91--1.12    0.901     669    4.6  0.99    0.89--1.11    0.904   0.95    0.85--1.07    0.432
  70--79                                                 566                                                        7.0                           1.06    0.95--1.19    0.280   1.01    0.89--1.14    0.893     417    4.3  1.00    0.88--1.13    0.937   0.92    0.80--1.06    0.227
  ≥80                                                    41                                                         6.5                           1.26    0.92--1.74    0.153   1.03    0.74--1.43    0.873     33     4.1  1.19    0.84--1.69    0.330   0.94    0.65--1.35    0.721
  Sex                                                                                                                                                                                                                                                                         
  Male                                                   1,670                                                      7.5                           Ref                           Ref                            1,290   4.6  Ref                           Ref                 
  Female                                                 534                                                        7.5                           1.02    0.93--1.13    0.645   0.92    0.83--1.03    0.135     410    4.6  1.01    0.90--1.13    0.909   0.93    0.83--1.05    0.251
  Performance status                                                                                                                                                                                                                                                          
  0 or 1                                                 1,220                                                      8.3                           Ref                           Ref                             902    4.8  Ref                           Ref                 
  ≥2                                                     152                                                        4.7                           1.73    1.46--2.06   \<0.001  1.61    1.36--1.92   \<0.001    114    2.9  1.53    1.26--1.87   \<0.001  1.39    1.14--1.70    0.001
  Unknown                                                832                                                        6.8                           1.20    1.09--1.31   \<0.001  1.16    1.06--1.27    0.002     684    4.3  1.14    1.03--1.26    0.011   1.14    1.02--1.26    0.016
  Comorbidities                                                                                                                                                                                                                                                               
  0                                                      805                                                        7.6                           Ref                           Ref                             652    4.8  Ref                           Ref                 
  1                                                      621                                                        7.0                           0.94    0.84--1.04    0.233   0.94    0.84--1.05    0.272     475    4.1  0.95    0.85--1.08    0.442   0.97    0.85--1.10    0.600
  ≥2                                                     702                                                        7.6                           1.00    0.90--1.11    0.975   0.96    0.86--1.07    0.460     538    4.7  0.97    0.87--1.09    0.654   0.95    0.84--1.07    0.414
  Unknown                                                76                                                        10.5                           0.69    0.54--0.88    0.003   0.70    0.54--0.89    0.004     35     6.2  0.77    0.55--1.09    0.140   0.74    0.52--1.05    0.088
  Tumor location                                                                                                                                                                                                                                                              
  Esophagus                                              1,014                                                      7.8                           Ref                           Ref                             772    4.6  Ref                           Ref                 
  Gastroesophageal junction or cardia                    410                                                        7.6                           0.95    0.85--1.07    0.395   0.95    0.84--1.08    0.417     316    5.0  0.90    0.79--1.03    0.131   0.92    0.80--1.06    0.268
  Stomach                                                780                                                        6.9                           1.08    0.98--1.18    0.132   1.02    0.91--1.15    0.698     612    4.4  0.98    0.88--1.09    0.691   0.98    0.85--1.12    0.729
  Histology                                                                                                                                                                                                                                                                   
  Adenocarcinoma                                         2,056                                                      7.6                           Ref                           Ref                            1,580   3.7  Ref                           Ref                 
  Squamous cell carcinoma                                128                                                        6.5                           1.24    1.03--1.48    0.021   1.22    1.01--1.48    0.040     104    4.7  1.40    1.15--1.71    0.001   1.13    1.08--1.67    0.008
  Carcinoma NOS                                          20                                                         4.6                           1.54    0.99--2.40    0.054   1.44    0.92--2.25    0.112     16     3.1  1.27    0.77--2.07    0.347   1.03    0.73--2.00    0.452
  Liver metastasis                                       1,169                                                      7.4                           0.98    0.90--1.07    0.628   1.17    1.06--1.29    0.002     920    4.6  1.00    0.90--1.10    0.943   1.22    1.01--1.26    0.041
  Distant lymph node metastasis                          890                                                        7.2                           1.06    0.97--1.15    0.226   1.17    1.07--1.29    0.001     684    4.5  0.97    0.88--1.07    0.571   1.16    0.92--1.14    0.620
  Peritoneal metastasis                                  524                                                        6.9                           1.22    1.11--1.35   \<0.001  1.42    1.25--1.61   \<0.001    385    4.1  1.11    0.99--1.24    0.079   1.31    1.05--1.41    0.009
  Lung metastasis                                        430                                                        7.0                           1.09    0.98--1.21    0.122   1.16    1.04--1.29    0.010     327    4.1  1.14    1.01--1.29    0.032   1.13    1.02--1.32    0.021
  Other metastases locations                             499                                                        6.6                           1.25    1.13--1.39   \<0.001  1.35    1.22--1.50   \<0.001    379    4.1  1.23    1.09--1.38   \<0.001          1.16--1.47   \<0.001
  Year of diagnosis                                                                                                                               0.95    0.93--0.97   \<0.001  0.97    0.95--0.99    0.009                 1.00    0.97--1.02    0.724   1.02    0.99--1.05    0.230

Cox regression analyses in patients diagnosed between 2010 and 2016 for overall survival and patients between 2010 and 2015 for time to failure of first‐line treatment. Both univariable and multivariable analyses are displayed for first‐line systemic therapy subdivided in strategies (Table [2a](#ijc32580-tbl-0002){ref-type="table"}) as well as regimens (Table [2b](#ijc32580-tbl-0003){ref-type="table"}). Hazard ratios were adjusted for age, sex, performance status, number of comorbidities, tumor location, histology, metastases locations and year of diagnosis. Systemic treatment strategies were divided in chemotherapy regimens (monotherapy, doublet and triplet), trastuzumab‐containing regimens and nontrastuzumab targeted therapy‐containing regimens. Systemic treatment regimens were dived as follows: monotherapy; fluoropyrimidine doublets (with a platinum \[but not cisplatin\], taxane or irinotecan); cisplatin doublets (with a fluoropyrimidine, taxane or etoposide); gemcitabine doublets (with a platinum/cisplatin); platinum (but not cisplatin)/taxane doublets; anthracycline triplets (with a fluoropyrimidine and platinum/cisplatin); taxane triplets (with a fluoropyrimidine and platinum/cisplatin); trastuzumab‐containing regimens; and (nontrastuzumab) targeted therapy‐containing regimens.

Abbreviations: A, anthracycline; C, cisplatin; CI, confidence interval; E, etoposide; F, fluoropyrimidine (capecitabine or 5‐FU); G, gemcitabine; HR, hazard ratio; I, irinotecan; NOS, not otherwise specified; OS, overall survival; P, platinum compound (oxaliplatin or carboplatin); T, taxane; TTF, time to failure.

Neither cisplatin, gemcitabine or platinum--taxane doublets nor anthracycline triplets showed survival benefit over fluoropyrimidine doublets in multivariable analyses (Table [2b](#ijc32580-tbl-0003){ref-type="table"}). OS and TTF of taxane triplets were significantly better than in fluoropyrimidine doublets (HR 0.63, 95% CI 0.46--0.86; HR 0.67, 95% CI 0.45--1.00). Both trastuzumab‐ and targeted therapy‐containing regimens showed significantly better OS and TTF than fluoropyrimidine doublets as well.

###### 

Cox regression analyses for overall survival and time to failure of first‐line treatment per systemic treatment regimen

                                                         Overall survival (*n* = 2,204)    Time to failure of first‐line treatment (*n* = 1,700)                                                                                                                              
  ------------------------------------------------------ -------------------------------- ------------------------------------------------------- ------ ------------ --------- ------ ------------ --------- ------- ----- ------ ------------ --------- ------ ------------ ---------
  Systemic therapy regimen                                                                                                                                                                                                                                                    
  Monotherapy                                            228                                                        4.1                           1.72    1.47--2.00   \<0.001  1.68    1.42--1.98   \<0.001    205    2.5  1.51    1.27--1.79   \<0.001  1.63    1.35--1.96   \<0.001
  F‐doublet (FP, FT, FI)                                 611                                                        7.3                           Ref                           Ref                             369    4.4  Ref                           Ref                 
  C‐doublet (*CF*, CT, CE)                               26                                                         6.7                           0.97    0.65--1.47    0.901   0.80    0.52--1.24    0.313     20     4.2  1.05    0.67--1.65    0.833   0.86    0.52--1.41    0.541
  G‐doublet (GP, GC)                                     50                                                         4.7                           1.84    1.38--2.45   \<0.001  1.67    1.24--2.26   \<0.001    46     3.0  1.71    1.26--2.33   \<0.001  1.65    1.20--2.27    0.002
  PT‐doublet                                             293                                                        8.2                           0.93    0.81--1.08    0.342   0.88    0.76--1.03    0.115     248    5.5  0.91    0.78--1.07    0.272   0.86    0.72--1.03    0.093
  A‐triplet (ACF, AFOx)                                  708                                                        7.4                           0.97    0.87--1.09    0.620   0.94    0.83--1.05    0.271     638    4.8  0.89    0.78--1.02    0.085   0.91    0.80--1.05    0.197
  T‐triplet (TCF, FOxT)                                  50                                                        11.8                           0.61    0.45--0.82    0.001   0.63    0.46--0.86    0.003     28     6.0  0.67    0.45--0.99    0.047   0.67    0.45--1.00    0.047
  Trastuzumab‐containing regimen                         215                                                       11.2                           0.62    0.53--0.73   \<0.001  0.62    0.52--0.73   \<0.001    126    6.7  0.62    0.50--0.76   \<0.001  0.60    0.49--0.75   \<0.001
  Targeted therapy‐containing regimen (nontrastuzumab)   23                                                        11.9                           0.73    0.48--1.12    0.145   0.66    0.43--1.02    0.059     20     9.2  0.54    0.34--0.86    0.009   0.51    0.32--0.81    0.005
  Age, years                                                                                                                                                                                                                                                                  
  \<60                                                   741                                                        7.8                           Ref                           Ref                             581    4.8  Ref                           Ref                 
  60--69                                                 856                                                        7.5                           1.03    0.93--1.14    0.542   1.01    0.91--1.12    0.842     669    4.6  0.99    0.89--1.11    0.904   0.96    0.86--1.09    0.551
  70--79                                                 566                                                        7.0                           1.06    0.95--1.19    0.280   1.00    0.89--1.13    0.991     417    4.3  1.00    0.88--1.13    0.937   0.92    0.80--1.06    0.236
  ≥80                                                    41                                                         6.5                           1.26    0.92--1.74    0.153   0.99    0.71--1.38    0.933     33     4.1  1.19    0.84--1.69    0.330   0.92    0.64--1.32    0.646
  Sex                                                                                                                                                                                                                                                                         
  Male                                                   1,670                                                      7.5                           Ref                           Ref                            1,290   4.6  Ref                           Ref                 
  Female                                                 534                                                        7.5                           1.02    0.93--1.13    0.645   0.91    0.82--1.02    0.093     410    4.6  1.01    0.90--1.13    0.909   0.93    0.83--1.05    0.270
  Performance status                                                                                                                                                                                                                                                          
  0 or 1                                                 1,220                                                      8.3                           Ref                           Ref                             902    4.8  Ref                           Ref                 
  ≥2                                                     152                                                        4.7                           1.73    1.46--2.06   \<0.001  1.61    1.35--1.91   \<0.001    114    2.9  1.53    1.26--1.87   \<0.001  1.37    1.12--1.68    0.002
  Unknown                                                832                                                        6.8                           1.20    1.09--1.31   \<0.001  1.17    1.06--1.28    0.001     684    4.3  1.14    1.03--1.26    0.011   1.15    1.04--1.28    0.010
  Comorbidities                                                                                                                                                                                                                                                               
  0                                                      805                                                        7.6                           Ref                           Ref                             652    4.8  Ref                           Ref                 
  1                                                      621                                                        7.0                           0.94    0.84--1.04    0.233   0.94    0.84--1.04    0.227     475    4.1  0.95    0.85--1.08    0.442   0.96    0.85--1.09    0.542
  ≥2                                                     702                                                        7.6                           1.00    0.90--1.11    0.975   0.96    0.86--1.07    0.442     538    4.7  0.97    0.87--1.09    0.654   0.95    0.84--1.07    0.371
  Unknown                                                76                                                        10.5                           0.69    0.54--0.88    0.003   0.68    0.53--0.88    0.003     35     6.2  0.77    0.55--1.09    0.140   0.74    0.52--1.05    0.091
  Tumor location                                                                                                                                                                                                                                                              
  Esophagus                                              1,014                                                      7.8                           Ref                           Ref                             772    4.6  Ref                           Ref                 
  Gastroesophageal junction or cardia                    410                                                        7.6                           0.95    0.85--1.07    0.395   0.93    0.82--1.05    0.252     316    5.0  0.90    0.79--1.03    0.131   0.90    0.78--1.04    0.158
  Stomach                                                780                                                        6.9                           1.08    0.98--1.18    0.132   1.00    0.89--1.13    0.995     612    4.4  0.98    0.88--1.09    0.691   0.94    0.82--1.08    0.410
  Histology                                                                                                                                                                                                                                                                   
  Adenocarcinoma                                         2,056                                                      7.6                           Ref                           Ref                            1,580   3.7  Ref                           Ref                 
  Squamous cell carcinoma                                128                                                        6.5                           1.24    1.03--1.48    0.021   1.24    1.02--1.51    0.032     104    4.7  1.40    1.15--1.71    0.001   1.35    1.08--1.69    0.009
  Carcinoma NOS                                          20                                                         4.6                           1.54    0.99--2.40    0.054   1.59    0.99--2.53    0.053     16     3.1  1.27    0.77--2.07    0.347   1.30    0.76--2.20    0.337
  Liver metastasis                                       1,169                                                      7.4                           0.98    0.90--1.07    0.628   1.17    1.06--1.29    0.002     920    4.6  1.00    0.90--1.10    0.943   1.13    1.01--1.26    0.035
  Distant lymph node metastasis                          890                                                        7.2                           1.06    0.97--1.15    0.226   1.16    1.06--1.28    0.002     684    4.5  0.97    0.88--1.07    0.571   1.02    0.92--1.13    0.720
  Peritoneal metastasis                                  524                                                        6.9                           1.22    1.11--1.35   \<0.001  1.42    1.25--1.61   \<0.001    385    4.1  1.11    0.99--1.24    0.079   1.23    1.06--1.42    0.006
  Lung metastasis                                        430                                                        7.0                           1.09    0.98--1.21    0.122   1.15    1.03--1.29    0.015     327    4.1  1.14    1.01--1.29    0.032   1.16    1.02--1.31    0.024
  Other metastases locations                             499                                                        6.6                           1.25    1.13--1.39   \<0.001  1.35    1.21--1.50   \<0.001    379    4.1  1.23    1.09--1.38   \<0.001  1.30    1.15--1.47   \<0.001
  Year of diagnosis                                                                                                                               0.95    0.93--0.97   \<0.001  0.98    0.96--1.00    0.058                 1.00    0.97--1.02    0.724   1.02    0.99--1.05    0.136

Of note, if we performed a predictive model and added only add variables with *p* \< 0.1 on univariable analysis, this did not influence statistically significance of the hazard ratios of systemic therapy strategies or regimens in the multivariable models.

Toxicity {#ijc32580-sec-0014}
--------

Of 1,221 patients diagnosed in 2010--2014, systemic treatment toxicity grade 3--5 was reported in 27% (Table [3](#ijc32580-tbl-0004){ref-type="table"}). Trastuzumab‐containing regimens induced the highest complication rate (45%), followed by triplets (33%), doublets (21%) and monotherapy (17%). The complication rate differed significantly between the four subgroups (*p* \< 0.001).

###### 

Grade 3--5 toxicity in patients treated with monotherapy, doublet chemotherapy and triplet chemotherapy and patients who received a trastuzumab‐containing regimen between 2010 and 2014

  Grade 3--5 toxicity               Patients, *n* (%)   *p* value[1](#ijc32580-note-0008){ref-type="fn"}                                            
  --------------------------------- ------------------- -------------------------------------------------- ------------- ------------- ------------ ---------
  Patients without adverse events   801 (65.6%)         115 (70.1%)                                        327 (71.9%)   313 (61.3%)   36 (50.7%)   \<0.001
  Patients with adverse events      332 (27.2%)         28 (17.1%)                                         97 (21.3%)    166 (32.5%)   32 (45.1%)   
  Grade 3--4                        314                 26                                                 92            159           29           
  Grade 5                           18                  2                                                  5             7             3            
  Unknown                           88 (7.2%)           21 (12.8%)                                         31 (6.8%)     32 (6.3%)     3 (4.2%)     
                                    Events, *n*                                                                                                     
  Number of adverse events          486                 36                                                 135           245           54           

Chi‐square test: adverse event rate monotherapy *vs*. doublet *vs*. triplet *vs*. trastuzumab‐containing regimens. Toxicity of patients who received targeted (nontrastuzumab) therapy (*n* = 20) was not displayed separately.

Of 486 reported adverse events, the most common causes were gastrointestinal complications (43%), followed by blood and lymphatic system disorders, including infections (21%), general disorders (fatigue, pain) and administration site conditions (7%), cardiovascular (6%) and metabolism and nutrition disorders (5%).

Eighteen patients died due to complications of systemic therapy, of whom 7 were treated with a triplet, 5 with a doublet, 2 with monotherapy and 3 with a trastuzumab‐containing regimen. Causes of death were blood and lymphatic system (*n* = 7), cardiovascular (*n* = 6) and gastrointestinal (*n* = 5) disorders.

Discussion {#ijc32580-sec-0015}
==========

In this nationwide cohort of 2,204 synchronous metastatic esophagogastric cancer patients, we found a strikingly wide variation of 45 different systemic therapy regimens that were administered between 2010 and 2016. This heterogeneity in treatment is undesirable, especially in case of unconventional treatment combinations, since second‐line treatment options are often registered under the assumption that certain compounds have been administered in the first line. The use of an unusual treatment regimen may limit opportunities for second‐line treatment and subsequent OS benefit. Analysis of beyond first‐line treatments is currently ongoing.

Current national and international guidelines recommend a fluoropyrimidine and platinum doublet in metastatic esophagogastric cancer patients, with the addition of an anthracycline or taxane in selected patients.[8](#ijc32580-bib-0008){ref-type="ref"}, [10](#ijc32580-bib-0010){ref-type="ref"}, [12](#ijc32580-bib-0012){ref-type="ref"}, [13](#ijc32580-bib-0013){ref-type="ref"}, [22](#ijc32580-bib-0022){ref-type="ref"} Until 2016, Dutch esophageal and gastric cancer guidelines advised systemic therapy only in patients with good performance status, without specifying the type of regimen.[23](#ijc32580-bib-0023){ref-type="ref"}, [24](#ijc32580-bib-0024){ref-type="ref"} This could have contributed to the heterogeneity in administered systemic therapy regimens. Another explanation for the variation could be that palliative treatment of esophagogastric cancer is not centralized in specialized hospitals in the Netherlands, in contrast to curative treatment.[25](#ijc32580-bib-0025){ref-type="ref"}, [26](#ijc32580-bib-0026){ref-type="ref"}

Since the added value of the addition of an anthracycline to a platinum--fluoropyrimidine doublet remains uncertain,[15](#ijc32580-bib-0015){ref-type="ref"}, [27](#ijc32580-bib-0027){ref-type="ref"}, [28](#ijc32580-bib-0028){ref-type="ref"}, [29](#ijc32580-bib-0029){ref-type="ref"} doublet chemotherapy tends to be the favored choice of first‐line palliative treatment because of its better tolerance.[4](#ijc32580-bib-0004){ref-type="ref"}, [5](#ijc32580-bib-0005){ref-type="ref"}, [6](#ijc32580-bib-0006){ref-type="ref"}, [14](#ijc32580-bib-0014){ref-type="ref"} In our study, we found less serious (grade 3--5) toxicity in patients receiving doublets (21%) compared to triplets (33%) as well as similar OS and TTF rates, which supports the shift toward doublet therapy as preferred strategy in these patients.

Taxane triplets showed superior OS and TTF compared to fluoropyrimidine doublets. From previous randomized studies, it is known that this increased effectiveness comes at the cost of more toxicity.[6](#ijc32580-bib-0006){ref-type="ref"} However, because of the limited number of patients who received a taxane triplet, definite conclusions from this real‐world population cannot be drawn. In the curative setting, docetaxel, oxaliplatin and 5‐FU/leucovorin (FLOT) showed longer survival in gastric cancer when used as a perioperative regimen as compared to anthracycline triplets.[30](#ijc32580-bib-0030){ref-type="ref"} The use of FLOT followed by resection with curative intent in patients with limited metastatic disease is currently being explored in the AIO‐FLOT5 trial.[31](#ijc32580-bib-0031){ref-type="ref"} However, in the palliative setting, it remains inconclusive whether first‐line taxane triplets or fluoropyrimidine doublets followed by second‐line taxanes should be preferred in view of survival benefit and toxicity.[6](#ijc32580-bib-0006){ref-type="ref"}, [11](#ijc32580-bib-0011){ref-type="ref"}

Monotherapy showed a significantly worse OS compared to doublets, which is in line with recently published reviews.[4](#ijc32580-bib-0004){ref-type="ref"}, [5](#ijc32580-bib-0005){ref-type="ref"}, [6](#ijc32580-bib-0006){ref-type="ref"} In addition, grade 3--5 toxicity rate was only marginally lower compared to doublets (18% *vs*. 21%, respectively). This could partly be caused by selection bias, since patients treated with monotherapy are more likely to have a poorer performance status. However, reported HRs were adjusted for both performance status and number of comorbidities. The use of no systemic treatment instead of monotherapy should therefore be considered in patients who potentially do not tolerate doublet therapy, since the median OS is comparable to that of patients who receive best supportive care only.[4](#ijc32580-bib-0004){ref-type="ref"}, [5](#ijc32580-bib-0005){ref-type="ref"}

A relatively high rate of grade 3--5 toxicity (45%) was seen in patients who received trastuzumab‐containing regimens. In the ToGA trial, trastuzumab did not induce more toxicity compared to chemotherapy only.[11](#ijc32580-bib-0011){ref-type="ref"} We did not observe the expected increase in cardiovascular toxicity due to trastuzumab. Possibly, the cytotoxic backbone induced the toxicity, since a toxicity rate of 56% was observed in patients who received a triplet backbone, compared to 43% with a doublet backbone. Moreover, lower toxicity rates were found in doublet backbones containing oxaliplatin (33%) compared to cisplatin‐containing doublet backbones (48%), which confirms previously described findings.[32](#ijc32580-bib-0032){ref-type="ref"}

Population‐based data represent a wide variation of patients, including frail patients and patients with comorbidity who are usually not included in conventional clinical trials. Real‐world evidence, if well analyzed and interpreted, is therefore highly potent in efficiently adding information about systemic treatment, alongside the results of these trials.[33](#ijc32580-bib-0033){ref-type="ref"}

We are aware that our study has possible limitations. Although the data have been checked and improved regularly, there could still have been some errors due to misinterpretations by data managers or inadequate reporting by physicians. Because of incomplete medical records, some variables were missing, which may have impaired adjustment for possible confounding. Furthermore, patients with solely head and neck lymph node metastases were excluded, because treatment could have consisted of definitive chemoradiotherapy with curative intent in the case of only positive supraclavicular lymph nodes, as well as patients who had long‐term radiotherapy alongside systemic treatment, since radiotherapy could affect survival rates.[20](#ijc32580-bib-0020){ref-type="ref"}, [34](#ijc32580-bib-0034){ref-type="ref"} Nevertheless, the vast majority of the metastatic esophagogastric cancer patient population who received systemic treatment is represented.

Our population‐level findings support doublet chemotherapy as the preferred first‐line treatment strategy in terms of survival rates and toxicity. A trastuzumab‐containing regimen should be considered in patients with HER2 overexpression. Future studies comparing first‐line palliative (doublet) treatment strategies, such as the LyRICX study (NCT03764553), should also focus on quality of life, since this is an important outcome in these patients. Moreover, possible predictive and prognostic characteristics that influence treatment outcomes should be taken into account to improve patient selection and personalize treatment strategies.[35](#ijc32580-bib-0035){ref-type="ref"}

In conclusion, in this nationwide study including real‐world evidence in first‐line systemic treatment of patients with synchronous metastatic esophagogastric cancer, doublet chemotherapy was associated with equal survival rates compared to triplet chemotherapy with a better toxicity profile. Patients treated with a trastuzumab‐containing regimen had the best survival. A remarkable heterogeneity of 45 different systemic therapy regimens was observed, which is undesirable since it may negatively affect outcomes in these patients.
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**Table S1** Baseline characteristics of all and selected metastatic esophagogastric cancer patients treated with systemic therapy and diagnosed between 2010 and 2014.
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**Table S2** List of assumptions regarding definitions of first‐line systemic treatment and time to failure of first‐line treatment.
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**Table S3** Most frequently administered systemic therapy regimens.
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**Figure S1** Word cloud of all 45 systemic therapy regimens that were administered. Font size of the word corresponds to the number of patients who received the regimen.
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**Figure S2** Subdivision of systemic therapy regimens. Systemic treatment regimens were dived as follows: monotherapy; fluoropyrimidine doublets (with a platinum \[but not cisplatin\], taxane, or irinotecan); cisplatin doublets (with a fluoropyrimidine, taxane or etoposide); gemcitabine doublets (with a platinum/cisplatin); platinum (but not cisplatin)/taxane doublets; anthracycline triplets (with a fluoropyrimidine and platinum/cisplatin); taxane triplets (with a fluoropyrimidine and platinum/cisplatin); trastuzumab‐containing regimens; and (nontrastuzumab) targeted therapy‐containing regimens. The colors of the lines correspond to the different doublet regimens, for example, fluoropyrimidine doublets consist of a fluoropyrimidine with either platinum (but not cisplatin) or taxane, as shown by the blue interconnecting lines.
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